Halozyme Therapeutics

At a glance

Halozyme Therapeutics reported 2025 revenue of $1.4B, up 37.6% from $1.02B in 2024. Over 4 years since 2021 ($443.3M), that is growth of about 33.2% a year. Operating margin was 33.6%, down from 62.2% in 2021. 2025 was the highest revenue year in this period.

In the last 12 months 5 insiders reported 0 open-market purchases and 24 sales ($48.4M). 22 of the sales were made under pre-arranged 10b5-1 plans. The largest was a sale of $6.6M by PRESIDENT AND CEO Helen Torley on Oct 8, 2026.

Halozyme Therapeutics filed 21 current reports (Form 8-K) in the last 12 months, most often for officer or director change (9), results of operations (5), material agreement (3) and new financial obligation (3). The latest officer or director change was reported on Sep 30, 2026. It reported a material agreement or a completed acquisition or disposal 3 times.

2 of the 20 investors tracked here held Halozyme Therapeutics at the last quarter end, worth $73.8M combined. It is the largest weight for Bridgewater Associates (0.1% of its portfolio), followed by Renaissance Technologies (0.1%). Reduced: Bridgewater Associates and Renaissance Technologies.

Annual results

Fiscal year ends Dec 31 · incorporated in DE

Tracked investors holding (13F)

Weight is the share of each investor's portfolio, as of the quarter end.